A Study on the Drug Utilization Pattern of Oral and Inhaled Corticosteroids among the COPD Patients

Authors

  • Manasa Reddipalli Department of Pharmacy Practice, GIET School of Pharmacy, Rajahmundry, Andhra Pradesh, India
  • Monika Mattaparthi Department of Pharmacy Practice, GIET School of Pharmacy, Rajahmundry, Andhra Pradesh, India
  • Naga Vamsi Naik Bhukya Department of Pharmacy Practice, GIET School of Pharmacy, Rajahmundry, Andhra Pradesh, India
  • Oselebe Somto Dave Department of Pharmacy Practice, GIET School of Pharmacy, Rajahmundry, Andhra Pradesh, India
  • Himasree Pithani Department of Pharmacy Practice, GIET School of Pharmacy, Rajahmundry, Andhra Pradesh, India
  • Dasaratha Dhanaraju Magharla Department of Pharmacy Practice, GIET School of Pharmacy, Rajahmundry, Andhra Pradesh, India

DOI:

https://doi.org/10.61427/jcpr.v1.i4.2021.42

Keywords:

COPD, Corticosteroids, Dyspnoea, Prednisolone

Abstract

Aim: To evaluate the drug utilization pattern of the oral & inhaled corticosteroids among the COPD patients. Materials & Methods: This was a prospective study. Patients of both genders who were diagnosed with COPD were included in the study. Patients with other respiratory disorders were excluded from the study. The severity of the dyspnoea was assessed by using MRC (Medical Research Council) dyspnoea scale. Results: Among the 200 study participants, 198 (99%) were males and 2 (1%) were females. About 52 (26%) study participants were observed with Grade 1 severity, 113 (56.5%) study participants with Grade 2 severity, 32 (16%) study participants were observed with Grade 3 severity and 3 (1.5%) study participants were observed with the Grade 4 severity of dyspnoea. Among the oral corticosteroids, Methyl Prednisolone was the most commonly prescribed drug followed by Deflazocort. Among the inhaled corticosteroids, Levosalbutamol + Beclomethasone combination was commonly prescribed followed by the combination Formetrol + Budesonide. Conclusion: In this study, most of the patients with COPD were observed with Grade 2 severity of dyspnoea followed by Grade 1 and Grade 3. Clinical pharmacist should involve along with the pulmonologist in the department of pulmonology in order to identify the trends of prescribing patterns and thereby providing better pharmaceutical care for the COPD patients.

Downloads

Download data is not yet available.

References

Devine JF. Chronic obstructive pulmonary disease: an overview. Am Health Drug Benefits. 2008; 1(7):34-42.

COPD available at: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd).

Koul PA. Chronic obstructive pulmonary disease: Indian guidelines and the road ahead. Lung India. 2013; 30(3):175-7.

Sood A. Indoor fuel exposure and the lung in both developing and developed countries: an update. Clin Chest Med. 2012; 33(4):649-65.

O Senn, EW Russi, M Imboden, NM Probst-Hensch. ?1-Antitrypsin deficiency and lung disease: risk modification by occupational and environmental inhalants. European Respiratory Journal, 2005; 26 (5): 909-17.

Stuckler D. Population causes and consequences of leading chronic diseases: A comparative analysis of prevailing explanations. Milbank Q. 2008; 86(2): 273-326.

Restrepo RD, Alvarez MT, Wittnebel LD, et al. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis. 2008; 3(3):371-84.

Mahmoodan Maryam, Nosenoor Mahesh, Ramdurga Bandenawaz. Drug utilization evaluation in chronic obstructive pulmonary disease patients. Der Pharmacia Lettre, 2017; 9(6): 153-62.

Published

2021-10-15
Statistics
431 Views | 294 Downloads
Citatons

How to Cite

Reddipalli, M., M. Mattaparthi, N. V. N. Bhukya, O. S. Dave, H. . Pithani, and D. D. Magharla. “A Study on the Drug Utilization Pattern of Oral and Inhaled Corticosteroids Among the COPD Patients”. Journal of Clinical and Pharmaceutical Research, vol. 1, no. 4, Oct. 2021, pp. 65-68, doi:10.61427/jcpr.v1.i4.2021.42.

Issue

Section

Research Articles